Thalidomide

COVID-19 in Germany

Novel drugs in the R/R MM: IMiDs

Ultra high-risk myeloma

Drug resistance in multiple myeloma

Iberdomide plus dex effective and well tolerated in R/R MM

Niels van de Donk

Myeloma XI long-term follow-up: Graham Jackson update

Does maintenance therapy increase overall survival in myeloma?

Andrew Spencer et al.

Toxicities of MM drug treatments

Highlights from IMW 2019 Part I

Francesca Gay et al.

MM: BTD plus a monoclonal antibody

Amrita Krishnan

Myeloma XI: Gareth Morgan update

Myeloma: immunomodulatory therapy and CHIP

Tarek H Mouhieddine

Treating MM: the European strategy

Induction in myeloma: a journey over time

Data from the Phase 3 CASSIOPEIA trial: D-VTd vs. VTd

Philippe Moreau

Myeloma XI trial: increased progression-free survival

Charlotte Pawlyn

1
2
3
Next